In a report released on March 22, Brian Abrahams from RBC Capital maintained a Buy rating on Hookipa Pharma (HOOK – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $0.71.
Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Gilead Sciences, and Biogen. According to TipRanks, Abrahams has an average return of 9.8% and a 50.60% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hookipa Pharma with a $4.67 average price target, a 556.73% upside from current levels. In a report released on March 22, JMP Securities also reiterated a Buy rating on the stock with a $5.00 price target.
HOOK market cap is currently $59.7M and has a P/E ratio of -0.78.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hookipa Pharma (HOOK) Company Description:
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body’s immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
Read More on HOOK:
- Hookipa Pharma reports Q4 EPS (22c), consensus (19c)
- HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- HOOK Earnings this Week: How Will it Perform?
- HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
- Hookipa Pharma Updates on Business Priorities and Partnerships
